Mobile

Phase 2, Dose-Ranging Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-004894-16

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To test the hypothesis that the ACR50 response after 24 weeks for the smallest dose that achieves at least 95% of the maximal efficacy (ED95) of LY2127399 is significantly greater than for placebo, when study drug is administered subcutaneously once monthly in patients with active RA despite ongoing MTX therapy.

Critère d'inclusion

  • Rheumatoid Arthritis

Liens